PRQR
ProQR Therapeutics NV
NASDAQ · Healthcare · Biotechnology · NL
$1.42
+3.28%Oct 28, 2026, 12:00 UTC
ProQR Therapeutics announced that it will present clinical and preclinical progress on AX-0810, AX-0811 and its Axiomer RNA editing platform at upcoming conferences.
Source:Sep 9, 2026, 12:00 UTC
ProQR Therapeutics dosed the first participant in the Phase 1 clinical trial of AX-0811 in healthy volunteers, marking the start of the study.
Source:Jun 25, 2026, 10:35 UTC
ProQR Therapeutics priced an underwritten registered direct offering of 27,624,310 ordinary shares at $1.81 per share for gross proceeds of $50.0 million.
Source: